Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro

被引:53
作者
Walker, JB
Hughes, B
James, I
Haddock, P
Kluft, C
Bajzar, L
机构
[1] Henerson Res Ctr, Hamilton, ON L8V 1C3, Canada
[2] McMaster Univ, Hamilton, ON L8V 1C3, Canada
[3] Pfizer Ltd, Global Res & Dev, Sandwich Labs, Sandwich CT13 9NJ, Kent, England
[4] TNO PG, Gaubius Inst, NL-2333 CK Leiden, Netherlands
关键词
D O I
10.1074/jbc.M205006200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Two competitive inhibitors of TAFIa (activated thrombin-activable fibrinolysis inhibitor), 2-guanidinoethyl-mercaptosuccinic acid and potato tuber carboxypeptidase inhibitor, variably affect fibrinolysis of clotted human plasma. Depending on their concentration, the inhibitors shortened, prolonged, or had no effect on lysis in vitro. The inhibitor-induced effects were both tissue-type plasminogenactivator(tPA) andTAFIa concentration- dependent. Inhibitor-dependent prolongation was favored at lower tPA concentrations. The magnitude of the prolongation increased with TAFIa concentration, and the maximal prolongation observed at each TAFIa concentration increased saturably with respect to TAFIa. A theoretical maximal prolongation of 20-fold was derived from a plot of the maximum prolongation versus TAFIa. This represents, for the first time, a measurement of the maximal antifibrinolytic potential of TAFIa in vitro. Because TAFIa spontaneously decays, the stabilization of TAFIa was investigated as a mechanism explaining the inhibitor-dependent prolongation of lysis. Both inhibitors stabilized TAFIa in a concentration-dependent, non-saturable manner. Although their K-1 values differed by three orders of magnitude, TAFIa was identically stabilized when the fraction of inhibitor-bound TAFIa was the same. The data fit a model whereby only free TAFIa decays. Therefore, the variable effects of competitive inhibitors of TAFla on fibrinolysis can be rationalized in terms of free TAFla and lysis time relative to the half-life of TAFIa.
引用
收藏
页码:8913 / 8921
页数:9
相关论文
共 31 条
[1]   The crystal structure of the inhibitor-complexed carboxypeptidase D domain II and the modeling of regulatory carboxypeptidases [J].
Aloy, P ;
Companys, V ;
Vendrell, J ;
Aviles, FX ;
Fricker, LD ;
Coll, M ;
Gomis-Rüth, FX .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) :16177-16184
[2]   TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J].
Bajzar, L ;
Morser, J ;
Nesheim, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16603-16608
[3]   PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].
BAJZAR, L ;
MANUEL, R ;
NESHEIM, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484
[4]   Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor [J].
Bajzar, L ;
Nesheim, M ;
Morser, J ;
Tracy, PB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (05) :2792-2798
[5]   The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent [J].
Bajzar, L ;
Nesheim, ME ;
Tracy, PB .
BLOOD, 1996, 88 (06) :2093-2100
[6]   SIMPLE METHOD FOR PREPARATION OF HOMOGENEOUS PHOSPHOLIPID VESICLES [J].
BARENHOLZ, Y ;
GIBBES, D ;
LITMAN, BJ ;
GOLL, J ;
THOMPSON, TE ;
CARLSON, FD .
BIOCHEMISTRY, 1977, 16 (12) :2806-2810
[7]   Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties [J].
Boffa, MB ;
Wang, W ;
Bajzar, L ;
Nesheim, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) :2127-2135
[8]   Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor [J].
Boffa, MB ;
Bell, R ;
Stevens, WK ;
Nesheim, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (17) :12868-12878
[10]  
EATON DL, 1991, J BIOL CHEM, V266, P21833